CHICAGO — Adjuvant dabrafenib plus trametinib reduced mortality risk for adults with resected stage III BRAF V600-mutant melanoma, according to final results of the randomized phase 3 COMBI-AD trial. The findings, presented at ASCO Annual Meeting, also reaffirmed 3- and 5-year updates on improved RFS and distant metastasis-free survival for individuals in the study’s treatment arm.
CHICAGO — Comprehensive prescription drug monitoring program mandates appeared associated with a moderate reduction in the number of opioid analgesics dispensed to people dying of cancer, according to study results.Reductions were two to three times higher among non-Hispanic Black and Asian/Pacific Islander decedents than non-Hispanic white decedents, findings presented at ASCO Annual
Ever taken a "ghost poop?" For a topic most people shy away from talking about in real life, bowel movements are an extremely popular subject of discussion.
Ever taken a "ghost poop?" For a topic most people shy away from talking about in real life, bowel movements are an extremely popular subject of discussion.
Ever taken a "ghost poop?" For a topic most people shy away from talking about in real life, bowel movements are an extremely popular subject of discussion.